Abbott Looking To Revive Generic Drug Sales With CFR Acquisition

The $2.9 billion deal (excluding CFR's $430 million debt) is expected to close by the end of the third quarter this year and be accretive to Abbott's earnings from Q4 2014 onward. The company expects CFR to generate $900 million in sales in 2015, and grow in the double digits over the next several years.